Aprea Therapeutics' APR-1051 Phase 1 Abstract Accepted at ASCO 2026

Aprea Therapeutics announced that an abstract detailing early results from its first-in-human Phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors has been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentation, titled "Early results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051)," will take place on May 30, 2026. This acceptance highlights progress in the clinical development of APR-1051, a key pipeline asset for the precision medicine oncology company.